Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.